• CEO interview: Growth Strategy of Shionogi

What's New

  • Show All
2020/03/27
FDA Accepts a New Drug Application for a New Formulation and Two Supplemental New Drug Applications for XOFLUZA® (Baloxavir Marboxil)
2020/03/26
Transcript of the R&D Meeting
2020/03/19
R&D Meeting
2020/03/17
Business Partnership with Micro Blood Science Inc. for an IgG/IgM Antibody-test Kit for COVID-19
2020/03/10
Partnership Agreement between Yabu City, Hyogo, and Shionogi on the Improvement of Community Healthcare
2020/03/09
Notice Regarding the Status and Completion of Acquisition of Own Shares(Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)
2020/03/06
Shionogi Certified as Health and Productivity Management Organization 2020 for Fourth Consecutive Year
2020/03/06
Shionogi and Tetra Therapeutics Entered into New Strategic Collaboration for BPN14770, the Drug Candidates for the Treatment of Brain Disorders Marked by Cognitive and Memory Deficits
2020/03/03
Shionogi Receives Grand Prize Company Award for Corporate Governance of the Year 2019
2020/03/03
SHIONOGI RECEIVES POSITIVE CHMP OPINION FOR FETCROJA® (CEFIDEROCOL) FOR THE TREATMENT OF INFECTIONS DUE TO AEROBIC GRAM-NEGATIVE BACTERIA IN ADULT PATIENTS WITH LIMITED TREATMENT OPTIONS
2020/02/25
SHIONOGI to Announce Executive Appointments, Corporate Reorganization and Personnel Reassignment
2020/02/25
Shionogi’s FETROJA® (cefiderocol) Now Available for the Treatment of Complicated Urinary Tract Infections in the U.S.
2020/02/07
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares(Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)